All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Neurology Product Name: Botox
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
Allergan Aesthetics and Allergan will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: GEN3013
Highest Development Status: Phase III Product Type: Large molecule
Recipient: Genmab
Deal Size: $3,150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
A USD 40 million milestone payment was triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator’s choice of chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DF1001,Pembrolizumab
Therapeutic Area: Oncology Product Name: DF1001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Recipient: Dragonfly Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 12, 2021
Details:
The opt-in grants AbbVie exclusive worldwide intellectual property rights to develop and commercialize products directed to this first specific target, developed using Dragonfly's TriNKET™ technology platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risankizumab
Therapeutic Area: Gastroenterology Product Name: Skyrizi
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Pennsylvania University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risankizumab
Therapeutic Area: Immunology Product Name: Skyrizi
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ibrutinib,Rituximab
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABBV-47D11
Therapeutic Area: Infections and Infectious Diseases Product Name: ABBV-47D11
Highest Development Status: Phase I Product Type: Large molecule
Recipient: Harbour BioMed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The fully human H2L2 transgenic Harbour Mice® platform enabled the quick discovery and development of several potent candidates of which ABBV-47D11’s cross-reactive neutralizing nature made it a compelling candidate to take it into development.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
